Bristol Myers' immunotherapy can now be used before and after surgery in the U.S. Elsewhere, J&J, Bayer, Bristol Myers Squibb and Pfizer are trimming staff.
BriaCell Therapeutics announced that its Bria-IMT cell therapy, plus an immune checkpoint inhibitor regimen, achieved ...
The approval came days before the FDA’s expected deadline and makes this the only PD-1 inhibitor approved for resectable ...
BeiGene has officially launched its PD-1 cancer drug Tevimbra in the U.S. more than six months after receiving a much-delayed ...
Opdivo’s approval for patients with resectable non-small cell lung cancer comes as the regulator recently raised concerns of ...
Having already been on a winding journey, Enjaymo, which Sanofi acquired through a 2018 buyout of Bioverativ, is now headed ...
A phase 2/3 non-inferiority study compared de-escalation strategies to standard chemoradiation in patients with human ...
Zacks.com on MSN18h
Bristol Myers Squibb (BMY) Advances While Market Declines: Some Information for InvestorsBristol Myers Squibb (BMY) closed at $54.20 in the latest trading session, marking a +0.82% move from the prior day. This change outpaced the S&P 500's 0.17% loss on the day. Meanwhile, the Dow lost 0 ...
Mean rates of colorectal cancer (CRC) screening tripled among average-risk individuals 45-49 years old after the U.S.
Hot on the tail of AstraZeneca’s Imfinzi, Bristol Myers Squibb’s PD-1/L1 inhibitor Opdivo has expanded its non-small cell lung cancer (NSCLC) net with an ...
WARN notices filed with the state show more job cuts due in the health sector as companies look to cut costs and streamline ...
On Wednesday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $53.76 which represents a slight increase of $0.86 or 1.63% from the prior close of $52.9. The stock opened at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback